FDA Grants NS-050/NCNP-03 Rare Pediatric Disease Designation in Duchenne Muscular Dystrophy

Published Date: 08 Dec 2024

A recently initiated phase 1/2 trial of NS-050/NCNP-03 will assess patients with Duchenne muscular dystrophy on dystrophin production, muscle strength, mobility, and functional exercise capacity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

2.

Detecting pancreatic cancer through changes in body composition and metabolism

3.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.

4.

The pandemic had little impact on mental health symptoms.

5.

Men over 75 years old may be significantly more likely to commit suicide if they have cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot